Small Interfering RNA Therapy for the Management and Prevention of Hypertension
Current Hypertension Reports,
Journal Year:
2025,
Volume and Issue:
27(1)
Published: Jan. 14, 2025
To
review
currently
existing
knowledge
on
a
new
type
of
antihypertensive
treatment,
small
interfering
RNA
(siRNA)
targeting
hepatic
angiotensinogen.
Targeting
angiotensinogen
synthesis
in
the
liver
with
siRNA
allows
reaching
suppression
renin-angiotensin
system
(RAS)
activity
for
up
to
6
months
after
1
injection.
This
might
revolutionize
as
it
could
overcome
non-adherence,
major
reason
inadequate
blood
pressure
control.
Animal
data
support
that
its
effects
and
end-organ
damage
are
fully
comparable
those
classical
RAS
blockers,
phase
I
II
clinical
trials
confirm
effectiveness
long-term
action.
Although
side
effect
profile
is
placebo-like,
also
pose
threat
patients
who
require
immediate
restoration
activity,
like
shock.
Here
tools
being
developed,
called
REVERSIR,
allow
annihilation
liver.
One
subcutaneous
injection
lowers
without
severe
effects.
The
decrease
can
be
reversed
drug
REVERSIR
if
needed.
Language: Английский
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
Nature Reviews Cardiology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 13, 2025
Language: Английский
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Drugs,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 19, 2025
Cardiovascular
disease
(CVD)
is
the
leading
cause
of
morbidity
and
mortality
in
patients
with
chronic
kidney
(CKD).
Quantitative
qualitative
changes
plasma
lipoprotein
profiles
are
frequently
associated
CKD
represent
a
significant
risk
factor
for
CVD
CKD.
Guidelines
from
European
Society
Cardiology
Atherosclerosis
classify
as
condition
high
or
very
cardiovascular
set
specific
low-density
cholesterol
targets.
Conventional
lipid-lowering
therapies
(LLTs),
such
statins,
ezetimibe,
fibrates,
can
control
CKD-associated
dyslipidemia
and,
to
some
extent,
prevent
major
atherosclerotic
events
CKD,
but
their
use
clinical
practice
presents
challenges
because
potential
renal
safety
concerns.
In
recent
years,
novel
ability
lower
both
triglycerides
have
been
introduced
market
(e.g.,
proprotein
convertase
subtilisin/kexin
type
9
inhibitors,
bempedoic
acid,
lomitapide,
volanesorsen)
improve
our
lipid
abnormalities.
However,
impact
on
functionality
has
not
fully
elucidated.
The
aim
this
review
was
examine
various
LLTs,
special
reference
medications,
highlight
important
considerations
guidance
these
medications
overt
degree
function
impairment.
We
underscore
lack
comprehensive
understanding
safety,
particularly
LLT
therapies,
strongly
emphasize
importance
future
dedicated
research
assess
efficacy
agents
Language: Английский
From clinical development to real-world outcomes with inclisiran
Current Opinion in Lipidology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 27, 2024
Purpose
of
review
Inclisiran
is
a
small
interfering
RNA
that
blocks
hepatocyte
production
the
PCSK9
(proprotein
convertase
subtilisin/kexin
type
9)
protein
by
specifically
targeting
PCKS9
mRNA
in
cytoplasm.
This
results
reduced
degradation
LDL
receptors
and
thus
lowers
cholesterol
around
50%
addition
to
other
lipid-lowering
therapies.
beyond
6
years
therapy.
covers
latest
published
data
outlines
future
studies
currently
process.
Recent
findings
To
date,
half
million
doses
have
been
given
worldwide
with
no
untoward
adverse
events
far.
The
twice-yearly
injections
make
it
potentially
very
user-friendly.
large
phase
3a
trials
saw
diminution
effect
time
up
nearly
7
years.
Very
3b
randomized
controlled
are
underway
may
produce
significant
reductions
major
cardiovascular
Summary
has
evaluated
numerous
trials,
primarily
ORION
9
26
,
10
27
11
28
studies,
which
demonstrated
patients
already
on
maximally
tolerated
statin
therapy,
biannual
inclisiran
52%
compared
placebo
good
safety
profile.
only
observed
side
effects
were
mild
transient
at
injection
site.
As
mentioned
accompanying
video,
this
adds
our
armamentarium
lipid
treatments.
Language: Английский
Debate: Lipid-lowering Therapies and Diabetes Development
Current Atherosclerosis Reports,
Journal Year:
2024,
Volume and Issue:
27(1)
Published: Dec. 1, 2024
Abstract
Purpose
of
Review
This
review
explores
the
relationship
between
lipid-lowering
therapies,
particularly
statins,
and
risk
new-onset
diabetes
(NOD).
It
examines
underlying
mechanisms
evaluates
whether
other
agents
present
similar
risks.
Recent
Findings
meta-analyses
further
underscore
a
dose-dependent
increase
in
NOD
with
statin
therapy,
high-intensity
statins.
In
contrast
to
LDL-cholesterol
lowering
drugs
their
impact
on
lipid
metabolism
liver,
genetic
experimental
studies
indicate
that
statins
may
impair
insulin
secretion
through
various
mechanisms,
including
alterations
small
G
protein
function,
calcium
signaling,
cholesterol
homeostasis
pancreatic
beta
cells.
might
contribute
increased
NOD.
Summary
Statins
effectively
reduce
cardiovascular
events
but
NOD,
potentially
via
intracellular
pathways
affecting
liver
beta-cell
function.
Despite
benefits
personalized
treatment
strategies
alternative
therapies
offer
safer
options
for
patients
at
diabetes,
shaping
future
clinical
guidelines
therapeutic
approaches.
Language: Английский